Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †

Cancers
Leontine SandforthHeiner Schäfer

Abstract

Metabolite exchange between stromal and tumor cells or among tumor cells themselves accompanies metabolic reprogramming in cancer including pancreatic adenocarcinoma (PDAC). Some tumor cells import and utilize lactate for oxidative energy production (reverse Warburg-metabolism) and the presence of these "reverse Warburg" cells associates with a more aggressive phenotype and worse prognosis, though the underlying mechanisms are poorly understood. We now show that PDAC cells (BxPc3, A818-6, T3M4) expressing the lactate-importer monocarboxylate transporter-1 (MCT1) are protected by lactate against gemcitabine-induced apoptosis in a MCT1-dependent fashion, contrary to MCT1-negative PDAC cells (Panc1, Capan2). Moreover, lactate administration under glucose starvation, resembling reverse Warburg co a phenotype of BxPc3 and T3M4 cells that confers greater potential of clonal growth upon re-exposure to glucose, along with drug resistance and elevated expression of the stemness marker Nestin and reprogramming factors (Oct4, KLF4, Nanog). These lactate dependent effects on stemness properties are abrogated by the MCT1/lactate-uptake inhibitor 7ACC2 or MCT1 knock-down. Furthermore, the clinical relevance of these observations was supporte...Continue Reading

References

Jul 1, 1996·The American Journal of Physiology·K J McCullaghA Bonen
Oct 21, 1998·Developmental Neuroscience·L PellerinP J Magistretti
Feb 24, 1956·Science·O WARBURG
Jul 24, 2008·International Journal of Cancer. Journal International Du Cancer·Susanne Sebens MüerkösterHeiner Schäfer
Nov 27, 2008·The Journal of Clinical Investigation·Gregg L Semenza
May 23, 2009·Science·Matthew G Vander HeidenCraig B Thompson
Dec 5, 2009·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Stephen PandolAnna Gukovskaya
Feb 9, 2011·The International Journal of Biochemistry & Cell Biology·Ubaldo E Martinez-OutschoornMichael P Lisanti
Jan 10, 2012·Gastroenterology·Mitsuro KandaMichael Goggins
Jan 10, 2012·Molecular Carcinogenesis·Erica C Nakajima, Bennett Van Houten
Mar 1, 2012·Differentiation; Research in Biological Diversity·Boris J N WinterhoffMarie-Luise Kruse
Mar 13, 2012·Journal of Bioenergetics and Biomembranes·Céline PinheiroFátima Baltazar
Mar 24, 2012·Cancer Cell·Patrick S Ward, Craig B Thompson
Sep 8, 2012·The Journal of Biological Chemistry·Go NagamatsuToshio Suda
Sep 13, 2012·Frontiers in Physiology·Anthony Evans, Eithne Costello
Nov 20, 2012·Pharmacology & Therapeutics·Mohita UpadhyayPerumal Vivekanandan
Dec 25, 2012·Cell·Jose M PoloKonrad Hochedlinger
Mar 20, 2013·Molecular Aspects of Medicine·Andrew P Halestrap
Oct 12, 2013·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Dec 18, 2013·Cancer Letters·Michael L O'ConnorWei Duan
May 2, 2014·BioMed Research International·M DistlerRobert Grützmann
Jul 6, 2014·Oncotarget·Elisabet CuyàsJavier A Menendez
Sep 26, 2014·Cancer Investigation·Alessandro AllegraCaterina Musolino
Mar 17, 2015·Stem Cell Reports·Shin-Il KimKnut Woltjen
Mar 21, 2015·Oncology Research and Treatment·Xiao Dong XuHai Tao Niu
Jun 18, 2015·Surgical Oncology·John A G MoirSteve A White
Sep 17, 2015·Cancer Research·Andrea VialeGiulio F Draetta
Oct 27, 2015·Oncotarget·Tao WangWei Duan
Dec 19, 2015·Stem Cells International·Maximilian ReichertGuido von Figura
Feb 16, 2016·Stem Cell Reports·Javier A MenendezTomás Alarcón
Feb 24, 2016·The Journal of Physiological Sciences : JPS·Tetsuya TakadaEishi Ashihara
May 25, 2016·British Journal of Cancer·Patricia SanchoChristopher Heeschen
Mar 9, 2017·Nature·Maria J Rodríguez-ColmanBoudewijn M T Burgering
Apr 20, 2017·Frontiers in Cell and Developmental Biology·Jennifer M JohnsonUbaldo E Martinez-Outschoorn

❮ Previous
Next ❯

Software Mentioned

QuantityOne
Excel

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.